Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for June 4, 2020

6/4/2020

 
Regulatory Update
 
Chi-Med plans to initiate a rolling NDA at the end of 2020 for surufatinib as a treatment of advanced neuroendocrine tumors.  
 
CHMP recommended that the EMA approve Ad26.ZEBOV and MVA-BN-Filo to prevent Ebola virus infection. The J&J Ebola vaccine is a two injection series. Zabdeno (Ad26.ZEBOV) is given first and followed two months later by Mvabea (MVA-BN-Filo).
 
Announced Research Updates
 
BioMarin announced that in a 4-year, 15 patient, Phase I/II, open-label extension trial, treatment with valoctocogene roxaparvovec resulted in a cumulative annualized bleeding rate of < 1, but Factor VIII levels declined while remaining in a range to provide hemostatic efficacy. Valoctocogene roxaparvovec is undergoing a priority review of its BLA due to being designated a Breakthrough Therapy. The drug has a PDUFA date of 8/21/2020.
 
Immutep announced interim data from the 109-patient, Phase II, open-label TACTI-002 trial evaluating eftilagimod alpha plus pembrolizumab in the treatment of patients with non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC). The data suggested an overall response rate (ORR) of 53% in 17 NSCLC patients and 39% in 18 patients with HNSCC.
 
Iterum Therapeutics announced that in the 1,395 patient, Phase III SURE 2 trial, IV sulopenem followed by oral sulopenem/probenecid did not meet non-inferiority compared to IV ertapenem followed by oral ciprofloxacin/metronidazole or amoxicillin-clavulanate in the treatment of complicated urinary tract infections.
 
Aveo  announced that in the 38-month, 350 patient, Phase III, TIVO-3 trial, of patients treated with tivozanib, progression-free survival (PFS) was not significantly different from sorafenib (16.4 vs 19.2 months) in patients with highly refractory advanced or metastatic renal cell carcinoma that had failed at least two prior therapies, including a vascular EGFR TKI. (Note: results after 19-months have been published and suggested a PFS of 5.6 months with tivozanib compared to 3.9 months with sorafenib.
 
Blueprint announced results from the 116 patient, Phase I/II, open label, ARROW trial. In the RET fusion–positive non-small cell lung cancer cohort, treatment with pralsetinib resulted in a 73% objective response rate (ORR) in treatment-naïve patients and 61% in patients that were previously treated with platinum-based chemotherapy. In the cohort of patients with RET-mutant medullary thyroid cancer, treatment-naïve patients had an ORR of 74% and previously treated patients had an ORR of 60%. The FDA accepted the NDA for pralsetinib for the treatment of RET fusion–positive non-small cell lung cancer and set a PDUFA date of 11/23/2020.
 
Published Research Updates
 
In the 1-year, 291 patient, Phase II, HER2CLIMB trial, treatment with tucatinib in combination with trastuzumab and capecitabine resulted in time to intracranial progression or death (CNS-PFS) of 9.9 months and overall survival of 18.1 months compared to 4.2 months CNS-PFS and 12 months OS with trastuzumab and capecitabine alone in patients with HER2-positive breast cancer with brain metastases.
 
In the 48-week, 217 patient, Phase IIb BE ABLE 2 trial (a long-term follow-up to the Phase IIb BE ABLE 1 trial), 80 to 100% of bimekizumab responders maintained PASI90, 69-83% maintained PASI100 and 78-100% had an Investigator’s Global Assessment of 0/1.
 
In the 406 patient, Phase III ADVANCE study, 16% of patients treated with eflapegrastim developed severe neutropenia compared to 24% with pegfilgrastim in patients with early-stage breast cancer. 
 
In the 55 patient, Phase II, open-label, INSIGHT trial, treatment with tepotinib did not improve progression free survival compared to standard platinum doublet chemotherapy (4.9 vs 4.4 months) in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or MET amplification having acquired resistance to EGFR inhibition. However the trial was terminated early due to poor recruitment, so all analyses are considered to be exploratory.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.